Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...

Madrigal on Friday said a green light would make Rezdiffra the first medication approved in the E.U. for MASH, which is the fastest-growing indication for liver transplantation in Europe.

Rezdiffra is already approved and available in the US for adults with noncirrhotic MASH who have moderate to advanced liver fibrosis. If approved in Europe, Rezdiffra would hold the same indication.

With analysts predicting strong sales growth for the current year, these insights might significantly increase Rezdiffra’s market potential.

Rezdiffra is already approved and available in the US for adults with noncirrhotic MASH who have moderate to advanced liver fibrosis. If approved in Europe, Rezdiffra would hold the same indication.